Search Results
Your search for ,her matches 3362 pages
Showing 101 - 150
Case 2: Role of T-Cell–Redirected Therapies in Elderly Patients With Relapsed/Refractory Multiple Myeloma
This is Part 2 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with relapsed...
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
In patients with small cell lung cancer, second-line treatment with the bispecific T-cell engager tarlatamab-dlle (which targets the delta-like ligand 3 [DLL3]) vs standard-of-care chemotherapy appeared to significantly improve overall survival, progression-free survival, and patient-reported...
Advancing Geriatric Oncology: Where We Have Been and Where We Are Going
The aging population is rapidly growing, with the number of older adults rising steadily each year. In the 1980s, experts predicted a rise in the number of older patients with cancer, yet we were unprepared. The shortage of oncologists, along with many experienced clinicians retiring early, has...
Case 3: High-Grade Astrocytoma
This is Part 3 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade glioma. The...
Case 1: Low-Grade Oligodendroglioma
This is Part 1 of Personalizing Therapy for Patients With Glioma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nimish Mohile, Stephen Bagley, and Yoshie Umemura discuss the treatment of a patient with low-grade...
Does Menopausal Hormone Therapy Increase the Risk of Death in Women With BRCA-Mutated Breast Cancer?
The risk of death does not appear to increase with the use of menopausal hormone therapy in women with early-onset, BRCA-mutated breast cancer who began hormone supplementation after diagnosis, based on preliminary data presented during the 2025 ASCO Annual Meeting.1 “Management of early surgical...
Realizing the Full Potential of Patient Engagement in Clinical Research
Nothing about us without us is a centuries-old value that is a cornerstone of meaningful patient engagement in clinical research. Such engagement has not been automatic and is still largely absent in geriatric oncology research, where older patients traditionally have been excluded from clinical...
ASTRO Announces New President-Elect, Officers
The members of the American Society for Radiation Oncology (ASTRO) recently elected four new officers to ASTRO’s Board of Directors: Catheryn M. Yashar, MD, FASTRO, President-Elect Jonathan Strauss, MD, MBA, Secretary/Treasurer-Elect Anita Mahajan, MD, FASTRO, Health Policy Council Vice Chair...
Immunotherapy Combination: A Potential New Standard in Triple-Negative Breast Cancer
In the phase III ASCENT-04/KEYNOTE-D19 trial, the combination of the TROP2-directed antibody-drug conjugate sacituzumab govitecan-hziy plus the PD-1 inhibitor pembrolizumab in previously untreated patients with PD-L1–positive advanced triple-negative breast cancer significantly reduced the risk of...
Case 3: Low-Grade Platinum-Resistant Ovarian Cancer
This is Part 3 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of low-grade platinum-resistant...
Case 2: HER2-Positive Platinum-Resistant Ovarian Cancer
This is Part 2 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of HER2-positive...
Case 1: FRα-Positive, High-Grade, Platinum-Resistant Ovarian Cancer
This is Part 1 of Targeted Treatment Options in Platinum-Resistant Ovarian Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Oladapo Yeku, Fernanda Musa, and Ying Liu discuss the treatment of high-grade platinum-resistant ...
Case 3: Newly Diagnosed Limited-Stage Small Cell Lung Cancer
This is Part 3 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss treatment of newly diagnosed limited-stage small cell ...
Case 1: Relapsed Small Cell Lung Cancer
This is Part 1 of Emerging Treatment Options for Small Cell Lung Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. David Spigel, John Heymach, and Lauren Byers discuss the treatment of relapsed small cell lung cancer...
W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award
W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...
ASCO Honors Karen Eubanks Jackson of Sisters Network® Inc. With 2025 Patient Advocate Award
Karen Eubanks Jackson, founder and Chief Executive Officer of Sisters Network® Inc. (SNI), has been named the recipient of the 2025 Patient Advocate Award by ASCO, Conquer Cancer, and the ASCO Foundation. The awards ceremony was held during the 2025 ASCO Annual Meeting. (See a video with Ms....
Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...
Case 1: First-Line Treatment of HR-Positive, HER2-Negative Metastatic Breast Cancer With ESR1 Y537S Mutation
This is Part 1 of The Role of Oral SERDs in Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Komal Jhaveri, Erika Hamilton, and Aditya Bardia discuss the treatment of a 61-year-old female patient who...
Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer
In the phase III DESTINY-Breast09 trial, first-line treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) plus the monoclonal antibody pertuzumab significantly delayed disease progression by more than 1 year—nearly doubling the time of disease control—over standard...
ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions
The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...
Case 1: Isolated Brain Relapse in HER2-Positive Breast Cancer
This is Part 1 of Novel Therapies for HER2-Positive Breast Cancer Brain Metastases, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Carey Anders, Rani Bansal, and Sarah Sammons discuss the treatment of a patient with a cT2N1,...
Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer
Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...
Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...
Case 1: Initial Management of a Patient With High-Risk Myelofibrosis
This is Part 1 of Expert Perspectives on the Treatment of High-Risk Myelofibrosis, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Abdulraheem Yacoub, Gabriela Hobbs, and Douglas Tremblay discuss the treatment of a 67-year-old ...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer
A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improved disease-free survival and overall survival, as well as patient-reported physical functioning and health-related fitness, in patients with stage III or high-risk stage II colon cancer. These...
Karen Eubanks Jackson on Receiving the 2025 ASCO Patient Advocate Award
Karen Eubanks Jackson, Founder and Chief Executive Officer of Sisters Network Inc. and recipient of the 2025 ASCO Patient Advocate Award, discusses her 30-year-long effort to support patients with breast cancer in the Black community. Sisters Network is focused on raising awareness of early...
Impact of Empirical Dietary Inflammatory Pattern on Survival Outcomes in Patients With Stage III Colon Cancer
Greater intake of a proinflammatory dietary pattern may be linked to worse overall survival in patients with stage III colon cancer who have undergone curative-intent resection. Sara K. Char, MD, a clinical fellow at Dana-Farber Cancer Institute, Boston, presented the results of a prospective...
How Family Adventures, Precision Oncology, and Living Purposefully Bring Balance to the Life of Charu Aggarwal, MD, MPH, FASCO
At just 5 years old, Charu Aggarwal, MD, MPH, FASCO, already knew that she wanted to be a physician when she grew up, although she can’t explain where the idea came from. She just knows the desire to help others was ingrained in her from a very early age. Growing up in New Delhi, India, where...
The Legal Impacts on Oncology Care of Prohibiting Diversity, Equity, and Inclusion Efforts
In January 2025, the Trump Administration issued executive orders asserting opposition to diversity, equity, and inclusion (DEI) programs on the federal level1,2 and rescinding Biden Administration orders that emphasized the importance of these efforts to promote equal opportunity across government ...
ASCO Congratulates 2025 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2025 ASCO Annual Meeting. “The recipients of this year’s...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of OSUCCC-James
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
Case 3: Refractory AML with Complex Karyotype and TP53 Mutation
This is Part 3 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Case 2: Relapsed/Refractory FLT3-Mutant AML
This is Part 2 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
Case 1: Relapsed KMT2A-Rearranged AML
This is Part 1 of Navigating the Complexities of Relapsed/Refractory AML: Identifying Mutations and Optimizing Targeted Therapy, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Uma Borate, Naval Daver, and Joshua Zeidner...
AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial results were presented by Anisha B. Patel, MD, Associate Professor of Dermatology, Deputy Chair of...
Case 3: Third-Line Treatment of CLL With Deletion 13q, Trisomy 12, and Unmutated IGHV
This is Part 3 of Treatment Approaches to Relapsed/Refractory CLL: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nicole Lamanna, John Allan, and Inhye Ahn discuss the third-line treatment of chronic...
W. Kimryn Rathmell, MD, PhD, FASCO, Named CEO of The Ohio State’s James Cancer Hospital and Solove Research Institute
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J....
Case 1: Patient With Poor-Risk Metastatic RCC
This is Part 1 of New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel George, Michael Harrison, and Catherine Fahey discuss the treatment of a patient ...
Karen E. Knudsen, MBA, PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO). A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen joins PICI at a pivotal time ...
Use of Investigational Tool to Detect Advanced-Stage Invasive Cervical Cancer
At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, Kersten Rothnie, MBBS, a gynecologic oncology fellow at Northwell Health in New York City, shared study findings on an investigational tool on behalf of her colleagues.1 These results suggested the presence of...
SGO’s President-Elect Brings Professional Experience and Passion to Her New Role
Society of Gynecologic Oncology (SGO) President-Elect Karen Lu, MD, assumed her official duties on March 17, 2025. Dr. Lu, who is also Executive Vice President and Physician-in-Chief at Moffitt Cancer Center in Tampa, Florida, brings many years of professional experience and active SGO membership...
Renowned Breast Cancer Physician-Scientist Hope S. Rugo, MD, FASCO, to Lead Women’s Cancers Program at City of Hope
Hope S. Rugo, MD, FASCO, recently joined the staff of City of Hope as the new Director of the Women’s Cancers Program, Division Chief of Breast Medical Oncology, and Professor in the Department of Medical Oncology and Therapeutics Research. In her role, she will lead and enhance City of Hope’s...
Parasitic Infection and Its Treatment Linked to Cancer-Related Gene Activity in the Cervix
New research has revealed that Schistosoma haematobium, a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment. Presented at ESCMID Global 2025, this pivotal study sheds new light ...
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
Patients with active cancer who developed venous thromboembolism (VTE) and were treated with anticoagulants for at least 6 months, followed by an additional 12 months of low-dose apixaban, experienced similar VTE recurrences and less bleeding as similar patients who received a full dose of the oral ...
Parker Institute for Cancer Immunotherapy Names New CEO
The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...
Case 2: Progression After First-Line CDK4/6 Inhibitors in ER-Positive Metastatic Breast Cancer
This is Part 2 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss how to approach the...
Bringing Palliative Care to Every Patient With Cancer
Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...
